Medicine and Dentistry
Patient
100%
Therapeutic Procedure
100%
Patient with Inflammatory Bowel Disease
76%
Immune Checkpoint Inhibitor
33%
Biosimilar
33%
Enterocolitis
33%
Quality of Life
25%
Drug
23%
Adverse Event
23%
Faecal Calprotectin
20%
Spontaneous Remission
20%
Health Care Cost
16%
Disease Activity
15%
Vedolizumab
13%
Therapeutics
12%
Patient Satisfaction
12%
Biological Marker
11%
Adult
8%
Injection
8%
Gut
7%
Off-Label Use
6%
Integrin
6%
Ipilimumab
6%
Infliximab
6%
Follow up
6%
Side Effect
6%
Corticosteroid
6%
Cohort Study
5%
Hospital
5%
Disease
5%
Subgroup Analysis
5%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammatory Bowel Disease
33%
Enterocolitis
28%
Remission
17%
Vedolizumab
11%
Calgranulin
8%
Ipilimumab
5%
Nivolumab
5%
Biosimilar Agent
5%
Infliximab
5%
Ulcer
5%
Immunology and Microbiology
Vedolizumab
67%
Blood Plasma
8%
Ipilimumab
6%
Programmed Death 1 Receptor
6%
Infliximab
5%
Biosimilar Agent
5%
Large Intestine
5%
Nivolumab
5%
